<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Budesonide (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Budesonide (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Budesonide (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="99269" href="/d/html/99269.html" rel="external">see "Budesonide (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26835074"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Uceris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871873"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Entocort;</li>
<li>Uceris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26819956"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Rectal</li></ul></div>
<div class="block doa drugH1Div" id="F26979914"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3504104-5393-4688-8e87-33480a9459f0">Ulcerative colitis, mildly to moderately active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mildly to moderately active (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as alternative monotherapy for distal disease in patients who cannot tolerate preferred topical agents, or in combination with other therapies (eg, oral agents) for refractory distal, left-sided, or extensive colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal foam:</b> 2 mg (one metered dose) once or twice daily for 2 weeks, followed by 2 mg (one metered dose) once daily at bedtime for 4 weeks; may be extended an additional 2 weeks if symptoms (eg, diarrhea, bleeding) persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-27416045','lexi-content-ref-26577683','lexi-content-ref-28779419','lexi-content-ref-31381615','lexi-content-ref-33832402','lexi-content-ref-25644096','lexi-content-ref-31865359','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-27416045','lexi-content-ref-26577683','lexi-content-ref-28779419','lexi-content-ref-31381615','lexi-content-ref-33832402','lexi-content-ref-25644096','lexi-content-ref-31865359','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal enema</b> [Canadian product]<b>:</b> Initial: ~2 mg (one enema) once daily at night prior to bedtime for 4 weeks; if remission is not induced may continue for additional 4 weeks (total therapy duration: 8 weeks).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992039"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Rectal foam: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely due to low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal enema [Canadian product]: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989277"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Rectal foam:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption. Monitor for increased signs and/or symptoms of hypercortisolism; discontinue use if signs or symptoms are observed.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal enema [Canadian product]: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F26979915"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F27368387"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Decreased plasma cortisol (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (4%), hpa-axis suppression, hypercortisolism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acne vulgaris, adrenal cortex hypofunction, agitation, allergic dermatitis, anaphylaxis, anxiety, depression, diarrhea, dizziness, drowsiness, dysphoria, emotional lability, exacerbation of diabetes mellitus, fever, flatulence, hyperacidity (peptic ulcer), hyperglycemia, hypertension, insomnia, maculopapular rash, pancreatitis, peripheral edema, pruritus, pseudotumor cerebri, skin rash, sleep disorder, urticaria</p></div>
<div class="block coi drugH1Div" id="F26819959"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to budesonide or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Entocort enema [Canadian product]: Hypersensitivity to budesonide or any component of the formulation; imminent bowel perforation as well as the probability of obstruction, abscess or other pyogenic infection, fresh intestinal anastomoses, extensive fistulas and sinus tracts; systemic or local bacterial, fungal, or viral infections; tuberculosis (TB) disease (active TB).</p></div>
<div class="block war drugH1Div" id="F26979545"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in patients receiving high doses for prolonged periods, or with concomitant CYP3A4 inhibitor use. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. In situations where patients are subject to surgery or other stress situations, supplementation with systemic glucocorticoids is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impaired adrenal suppression in patients transferred from other glucocorticoids: Monitor patients transferred from systemic corticosteroids to corticosteroids with lower systemic effects (eg rectal foam), since steroid withdrawal, including benign intracranial hypertension or acute adrenal suppression, may occur. Replacement of systemic corticosteroids with rectal foam may unmask allergies (eg, rhinitis and eczema) previously controlled by systemic drug. Adrenocortical function monitoring may be required in these patients; reduce dose cautiously.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; if exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG) may be needed; antivirals may be needed if chickenpox develops. Exposure to measles may require pooled intramuscular immunoglobulin use. Corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for viral hepatitis. Close observation is required in patients with tuberculosis (TB) infection (latent TB) and/or TB reactivity; restrict use in TB disease (active TB) (only in conjunction with antituberculosis treatment).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypertension, acute coronary disease, or limited cardiac reserve.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes or a family history of diabetes; may alter glucose production/regulation leading to hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; increased oral bioavailability has been reported in patients with cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma or a family history of these diseases; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged glucocorticoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disturbances: Systemic corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because of the risk of adverse effects, corticosteroids should be used cautiously in older adults at the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flammable contents: Rectal foam contains flammable propellants. Avoid fire, flame and smoking during and immediately following administration. Temporarily discontinue use before initiation of bowel preparation for colonoscopy; consult health care provider prior to resuming therapy.</p></div>
<div class="block dosfc drugH1Div" id="F51558382"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Each Uceris rectal foam canister contains 14 metered doses.</p></div>
<div class="block foc drugH1Div" id="F26835075"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uceris: 2 mg/actuation (33.4 g) [contains cetyl alcohol, edetate (edta) disodium, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg (33.4 g)</p></div>
<div class="block geq drugH1Div" id="F26835073"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F27265719"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Uceris Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/ACT (per gram): $14.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871874"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uceris: 2 mg/actuation (33.4 g) [contains cetyl alcohol, edetate (edta) disodium, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entocort: 0.02 mg/mL</p></div>
<div class="block adm drugH1Div" id="F26979920"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Rectal foam: For rectal use only; not for oral use. Wash hands before and after use. Prior to use, patients should use the bathroom to empty the bowel; when administering evening dose (immediately prior to bedtime), do not empty bowels again until the next morning if possible. Attach applicator to canister nozzle. Each applicator is coated with a lubricant. If additional lubrication is needed, petrolatum or petroleum jelly can also be used. Warm the canister in the hands while shaking it vigorously for 10 to 15 seconds prior to use. Unlock the canister by twisting the domed canister top until it is aligned with the nozzle. May be used in a standing, lying or sitting position (eg, while sitting on the toilet). Turn the canister upside down and gently insert applicator tip into rectum as far as is comfortable. Push down on the pump dome with forefinger and hold for 2 seconds; release finger pressure on pump dome and hold applicator in place for 10 to 15 seconds. After administering, applicators can only be used one time and should be discarded in provided plastic trash bag. Avoid fire, flame and smoking during and immediately following administration. Temporarily discontinue use before initiation of bowel preparation for colonoscopy; consult provider prior to resuming therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal enema [Canadian product]: For rectal use only; not for oral use. Remove cap after preparation and screw 1 nozzle (pouch labeled ‘applicator enema’) onto the bottle prior to administration. May lubricate nozzle with petroleum jelly to improve comfort. Patient should lie down on either side with bottom slightly higher than the rest of body, shake the reconstituted enema bottle, gently ease nozzle into the rectum as far as comfortable, and then empty most of contents into rectum (bottle designed to keep some solution after use). Patient should roll over on stomach and remain in this position for 5 minutes, then lie in a comfortable position. Enema should be retained the whole night if possible or as long as possible. An optional plastic bag (supplied) may be used to hold bottle during administration and easily dispose of the bottle after administration.</p></div>
<div class="block use drugH1Div" id="F26819958"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mildly to moderately active:</b> Remission induction in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge</p>
<p style="text-indent:-2em;margin-left:2em;">Entocort Enema [Canadian product]: Management of distal ulcerative colitis (rectum, sigmoid, and descending colon)</p></div>
<div class="block cyt drugH1Div" id="F26868941"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F26868938"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Budesonide (Topical). Management: Consider the risks of systemic corticosteroid adverse effects versus the benefits of coadministration. Monitor patients for systemic corticosteroid adverse effects if combined.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F26979560"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Grapefruit juice doubles bioavailability of oral budesonide by inhibiting gut mucosal CYP3A4; altered effects with rectal use are possible. Management: Grapefruit or grapefruit juice should be avoided during therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F54357370"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Fertility may be decreased in females with active inflammatory bowel disease. Corticosteroids used for the management of inflammatory bowel disease are not expected to decrease female fertility (AGA [Mahadevan 2019]).</p></div>
<div class="block pri drugH1Div" id="F26979541"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">Because systemic corticosteroids may increase the risk of gestational diabetes and other adverse pregnancy outcomes, use for maintenance therapy in pregnant women with inflammatory bowel disease is not recommended. However, corticosteroids may be used to treat disease flares in pregnant patients (AGA [Mahadevan 2019]).</p></div>
<div class="block brc drugH1Div" id="F26979543"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Budesonide can be detected in breast milk following oral inhalation; exposure to a breastfeeding child may be higher following maternal rectal use than oral inhalation.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed following oral use should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Corticosteroids used for inflammatory bowel disease are considered compatible with breastfeeding (AGA [Mahadevan 2019]).</p></div>
<div class="block dic drugH1Div" id="F26979919"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid consumption of grapefruit or grapefruit juice during treatment </p></div>
<div class="block mop drugH1Div" id="F26979922"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline hepatic function tests; serum glucose, electrolytes; presence of infection, signs/symptoms of hypercortisolism, blood pressure as clinically indicated.</p></div>
<div class="block pha drugH1Div" id="F26979562"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.</p></div>
<div class="block phk drugH1Div" id="F26979564"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rectal foam: Minimal; Rectal enema [Canadian product]: Rapid and essentially complete within 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 2.2 to 3.9 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 85% to 90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensive hepatic metabolism, primarily by CYP3A4 to 2 major metabolites (negligible glucocorticoid activity)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Rectal enema [Canadian product]: 3% to 27%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Rectal enema [Canadian product]: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Rectal enema [Canadian product]: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine: Oral dose: ~60%; Feces: ~30%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27001471"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort | Entocort rektal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Entocord</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Budecol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Budez</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rectabul</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Enemacort</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk | Entocort</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Budenofalk</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Entocort</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Entocord</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AlHashash.1">
<a name="AlHashash.1"></a>Al Hashash J, Regueiro M. Medical management of low-risk adult patients with mild to moderate ulcerative colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27416045">
<a name="27416045"></a>Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. Baseline oral 5-ASA use and efficacy and safety of budesonide foam in patients with ulcerative proctitis and ulcerative proctosigmoiditis: analysis of 2 phase 3 studies. <i>Inflamm Bowel Dis</i>. 2016;22(8):1881-1886. doi:10.1097/MIB.0000000000000860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/27416045/pubmed" id="27416045" target="_blank">27416045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EntocortEnema.1">
<a name="EntocortEnema.1"></a>Entocort Enema (budesonide) [product monograph]. Burlington, Ontario, Canada: C.R.I.; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308‐323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26577683">
<a name="26577683"></a>Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. <i>J Crohns Colitis</i>. 2016;10(7):828-836. doi:10.1093/ecco-jcc/jjv208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/26577683/pubmed" id="26577683" target="_blank">26577683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28779419">
<a name="28779419"></a>Naganuma M, Aoyama N, Tada T, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>J Gastroenterol</i>. 2018;53(4):494-506. doi:10.1007/s00535-017-1376-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/28779419/pubmed" id="28779419" target="_blank">28779419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381615">
<a name="31381615"></a>Naganuma M, Hirai F, Kobayashi K, et al; ESCORT study group. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. <i>PLoS One</i>. 2019;14(8):e0220413. doi:10.1371/journal.pone.0220413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/31381615/pubmed" id="31381615" target="_blank">31381615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33832402">
<a name="33832402"></a>Omori T, Saruta M, Nagaki A, et al. Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance. <i>Expert Opin Pharmacother</i>. 2021;22(11):1505-1511. doi:10.1080/14656566.2021.1905796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/33832402/pubmed" id="33832402" target="_blank">33832402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644096">
<a name="25644096"></a>Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. <i>Gastroenterology</i>. 2015;148(4):740-750.e2. doi:10.1053/j.gastro.2015.01.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/25644096/pubmed" id="25644096" target="_blank">25644096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31865359">
<a name="31865359"></a>Shibuya T, Nomura K, Okahara K, et al. Budesonide foam for ulcerative colitis patients experiencing inadequate response to biological therapy. <i>Med Sci Monit</i>. 2019;25:9855-9863. doi:10.12659/MSM.918562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-topical-drug-information/abstract-text/31865359/pubmed" id="31865359" target="_blank">31865359</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Uceris (budesonide) rectal foam [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 99268 Version 99.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
